Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
758 Results for "
large
" in MedChemExpress (MCE) Product Catalog:
Products (758)
758 Results for "large" in MCE Product Catalog:
Cat. No.: HY-L157
988 compounds
Natural product have great diversity and structural complexity of scaffolds. And the number of their drugs represents a large number of sources of new pharmacological entities, so natural products are of great significance in drug discovery. The Dictionary of Natural Products (DNP) shows that natural products mainly come from plants, animals and microorganisms, and animal sources are the second important source of natural products. Animal derived natural products exist to varying degrees in almost all forms of animals, generally secondary metabolite extracted from organisms.
MCE provides a unique collection of 988 animal-sourced natural products. MCE Animal-Sourced Natural Product Library is a useful tool for drug discovery that can be used for high throughput screening (HTS) and high content screening (HCS).
Cat. No.: HY-L187
2,196 compounds
Fragment-based drug development (FBDD) is a strategy for drug discovery that can be applied both academically and commercially to enhance the identification of some non-drug targets. Fragment-based drug development has identified low molecular weight molecules (<300 Da) capable of binding to related macromolecules. These fragments can cover a wide chemical space and are easy to optimize later. Currently, several fragment-based drugs have entered clinical trials, of which two drugs, Vemurafenib and Venetoclax, have been approved for marketing.
Based on Tanimoto coefficient, MCE uses similarity algorithm to carefully select 2,196 high-structurally diverse 'RO3' compliant fragment molecules from large-scale fragment molecules, which can be applied to fragment based drug development.
Cat. No.: HY-L084
939 compounds
Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine.
MCE provides a unique collection of 939 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.
Cat. No.: HY-L107
2,020 compounds
With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.
MCE offers a unique collection of 2,020 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.
Cat. No.: HY-P9959
CAS No.: 635715-01-4
Synonyms: CMC-544; PF-5208773; WAY-207294
Target:
Research Areas:
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody Inotuzumab (HY-P99264) conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-P9959A
CAS No.: 635715-01-4
Synonyms: CMC-544 (solution); PF-5208773 (solution); WAY-207294 (solution)
Target:
Research Areas:
Inotuzumab ozogamicin solution (CMC-544 solution) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to Calicheamicin (HY-19609). Inotuzumab ozogamicin solution and G544 bind human CD22 with similar affinities (Kd ≈ 150 pM). Inotuzumab ozogamicin solution has demonstrated efficacy against CD22 + B-cell non-Hodgkin’s lymphoma. Inotuzumab ozogamicin solution can be used in the research of acute lymphoblastic leukemia .
Cat. No.: HY-W673649
CAS No.: 108392-10-5
Target:
Research Areas:
N-Oleyl-sphingomyelin is a bilayer property lipid modulator with affinity for cholesterol bilayers. N-Oleyl-sphingomyelin reduces the amount of cholesterol required for liquid-ordered phase formation and enhances the cholesterol tolerance of membrane structures. N-Oleyl-sphingomyelin can be used in studies related to membrane lipid phase separation and lipid raft structures .
Cat. No.: HY-P81448A
Synonyms: SLC7A5; CD98LC, LAT1; MPE16; large neutral amino acids transporter small subunit 1; 4F2 light chain (4F2 LC; 4F2LC); CD98 light chain; Integral membrane protein E16; Solute carrier family 7 member 5
Cat. No.: HY-P87158
Synonyms: Adapter-related protein complex 1 subunit gamma-1 antibody; Adaptor protein complex AP 1 gamma 1 subunit antibody; Adaptor protein complex AP 1 subunit gamma 1 antibody; Adaptor protein complex AP-1 subunit gamma-1 antibody; Adaptor related protein complex 1 gamma 1 subunit antibody; ADTG antibody; AP 1 complex subunit gamma 1 antibody; AP-1 complex subunit gamma-1 antibody; AP1G1 antibody; AP1G1_HUMAN antibody; Adapter-related protein complex 1 subunit gamma-1 antibody; Adaptor protein complex AP 1 gamma 1 subunit antibody; Adaptor protein complex AP 1 subunit gamma 1 antibody; Adaptor protein complex AP-1 subunit gamma-1 antibody; Adaptor related protein complex 1 gamma 1 subunit antibody; ADTG antibody; AP 1 complex subunit gamma 1 antibody; AP-1 complex subunit gamma-1 antibody; AP1G1 antibody; AP1G1_HUMAN antibody; CLAPG1 antibody; Clathrin assembly protein complex 1 gamma 1 large chain antibody; Clathrin assembly protein complex 1 gamma large chain antibody; Clathrin assembly protein complex 1 gamma-1 large chain antibody; Clathrin associated/assembly/adaptor protein large gamma 1 antibody; Gamma1 adaptin antibody; Gamma1-adaptin antibody; Golgi adaptor HA1/AP1 adaptin gamma subunit antibody; Golgi adaptor HA1/AP1 adaptin subunit gamma 1 antibody; Golgi adaptor HA1/AP1 adaptin subunit gamma-1 antibody; MGC18255 antibody;
Cat. No.: HY-101913R
CAS No.: 2205034-18-8
IL-17A antagonist 1 (Standard) is the analytical standard of IL-17A antagonist 1 (HY-101913). This product is intended for research and analytical applications. IL-17A antagonist 1 is an interleukin-17A (IL-17A) antagonist with an IC50 of 1.14 μM and a Kd of 0.66 μM. IL-17A antagonist 1 binds specifically and exclusively to the IL-17A homodimer at its central dimer interface pocket, induces a large conformational change that widens the pocket, and disrupts the IL-17A/IL-17RA interaction. IL-17A antagonist 1 does not bind to IL-17F or IL-17RA .
Cat. No.: HY-137952
CAS No.: 875755-39-8
Target:
Research Areas:
NS8593 is an SK channel (small conductance Ca 2+-activated K+ channels) inhibitor. NS8593 reversibly inhibited recombinant SK3-mediated currents (human SK3 and rat SK3). NS8593 inhibits all the SK1-3 subtypes Ca 2+-dependently (Kd = 0.42, 0.60, and 0.73 μM, respectively, at 0.5 μM Ca 2+). NS8593 does not affect the Ca 2+-activated K channels of intermediate and large conductance (hlk and hBK channels, respectively). NS8593 can also inhibit TRPM7 (melastatin-related TRP cation channel 7) (IC50 = 1.6 mM). NS8593 can be used for the study of central nervous system (CNS) related diseases .
Research Areas:
GBD-9 is a degrader based on the E3 ubiquitin ligase CRBN that targets BTK and the G1 to S phase transition protein GSPT1. GBD-9 has both PROTAC and molecular glue properties by inducing ubiquitination and proteasomal degradation of target proteins. GBD-9 can efficiently degrade wild-type and mutant BTK (such as C481S mutation) and GSPT1. GBD-9 significantly inhibits tumor cell proliferation by inducing G1 phase arrest in cancer cells, downregulating anti-apoptotic proteins (BCL-2, MCL-1) and activating Caspase-3 to induce apoptosis. GBD-9 is mainly used in the research of hematological tumors such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) .
Cat. No.: HY-169481
CAS No.: 3027918-96-0
Research Areas:
AP-1 is a targeted ALK PROTAC degrader. AP-1 effectively degrades various ALK fusion/mutation forms, including degradation of NPM-ALK (DC50 = 4.6 nM) and EML4-ALK (DC50 = 357.6 nM), and exhibits a typical hook effect at high concentrations. AP-1 inhibits phosphorylation of downstream STAT3, downregulates gene expression in the JAK-STAT pathway, and kills ALK-positive tumor cells via activating the caspase-3-dependent apoptosis pathway. AP-1 shows cytotoxicity against a variety of cancer cells and possesses anti-tumor activity. AP-1 can be used in research related to non-small cell lung cancer, neuroblastoma, and anaplastic large cell lymphoma .
Cat. No.: HY-172736
CAS No.: 3005272-36-3
Synonyms: BMS-986458
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
Cat. No.: HY-18778C
CAS No.: 866399-89-5
Synonyms: TA-8995 hemicalcium; DEZ-001 hemicalcium; AMG-899 hemicalcium
Research Areas:
Obicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe (HY-17376) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia .
Cat. No.: HY-B0380
CAS No.: 39133-31-8
Target:
Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
Cat. No.: HY-B0380A
CAS No.: 34140-59-5
Target:
Opioid Receptor Toll-like Receptor (TLR) Calcium Channel Potassium Channel IRAK ERK JNK NF-κB Akt Apoptosis
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca 2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS) .
Cat. No.: HY-DY1097
CAS No.: 107091-89-4
Solvent and concentration: DMSO: 10 mM
The 1 mL volume is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
Cat. No.: HY-W107409
CAS No.: 213473-00-8
Category:
Target:
Cat. No.: HY-W713297
CAS No.: 2469734-82-3
Synonyms: ABOB hydrochloride-d8
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
